Does natalizumab therapy benefit patients with multiple sclerosis?

JAMA Neurol. 2014 Aug;71(8):945-6. doi: 10.1001/jamaneurol.2014.1201.

Authors

Olaf Stüve¹, Gary R Cutter²

Affiliations

¹ Veterans Affairs Medical Center, Neurology Section, Medical Service Dallas, Veterans Affairs North Texas Health Care System, Dallas2Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center at Dallas3Department of Neur.
² Section on Research Methods and Clinical Trials, Department of Biostatistics, University of Alabama at Birmingham.

PMID: 24979690
DOI: 10.1001/jamaneurol.2014.1201

No abstract available

Publication types

Editorial

MeSH terms

Antibodies, Monoclonal, Humanized / adverse effects
Antibodies, Monoclonal, Humanized / pharmacology*
Humans
Multiple Sclerosis / drug therapy*
Natalizumab
Risk Assessment
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
Natalizumab